R. Barst

发表

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

H. Ghofrani, R. Barst, O. Sitbon, 2009, Journal of the American College of Cardiology.

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

R. Barst, D. Ivy, D. Ivy, 2003, Clinical pharmacology and therapeutics.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

M. Gladwin, R. Woolson, R. Barst, 2011, Blood.

Clinical features of paediatric pulmonary hypertension: a registry study

G. Raskob, Z. Jing, R. Barst, 2012, The Lancet.

Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension.

R. Barst, E. Horn, J. Morse, 1999, Chest.

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.

R. Barst, E. Rosenzweig, D. Kerstein, 1999, Circulation.

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

G. Raskob, R. Benza, R. Barst, 2011, Chest.

Validation of two predictive models for survival in pulmonary arterial hypertension

M. Humbert, R. Benza, R. Barst, 2015, European Respiratory Journal.

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil

R. Barst, R. Naeije, G. Simonneau, 2006, European Respiratory Journal.

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

R. Barst, D. Badesch, A. Frost, 2006, Journal of the American College of Cardiology.

Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.

B. Groves, D. Stewart, R. Barst, 1999, Circulation.

Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles.

G. Sinha, R. Barst, S. Itescu, 1996, American journal of respiratory and critical care medicine.

Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension

R. Benza, R. Barst, D. Ivy, 2008, International journal of clinical practice. Supplement.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension

R. Barst, D. Ivy, D. Wessel, 2012, Circulation.

Pediatric pulmonary hypertension.

C. Thomson, T. Fleming, R. Dweik, 2013, Journal of the American College of Cardiology.

Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging.

L. Boxt, R. Barst, J. Katz, 1993, Journal of the American College of Cardiology.

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

G. Raskob, R. Benza, R. Barst, 2010, Chest.

Vasodilator therapy for primary pulmonary hypertension in children.

G. Maislin, A. Fishman, R. Barst, 1999, Circulation.

Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.

S. Hodge, K. Wilhelmsen, R. Barst, 1997, Circulation.

Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).

R. Barst, M. Mcgoon, D. Ivy, 2014, The American journal of cardiology.

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.

B. Brundage, H. Ghofrani, R. Barst, 2012, Journal of the American College of Cardiology.

Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.

R. Barst, D. Wax, R. Garofano, 1999, Chest.

Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension.

W. Gersony, R. Barst, J. Rhodes, 1991, Journal of the American College of Cardiology.

Effects of long-term bosentan in children with pulmonary arterial hypertension.

Steven H Abman, R. Barst, D. Ivy, 2005, Journal of the American College of Cardiology.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

M. Humbert, R. Barst, D. Badesch, 2005, Thorax.

STARTS-2: Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Pediatric Pulmonary Arterial Hypertension

R. Barst, D. Ivy, G. Layton, 2014, Circulation.

Primary pulmonary hypertension: immunogenetic response to high‐mobility group (HMG) proteins and histone

R. Barst, J. Morse, M. Fotino, 1996, Clinical and experimental immunology.

Tadalafil Therapy for Pulmonary Arterial Hypertension

B. Brundage, H. Ghofrani, R. Barst, 2009, Circulation.

Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective.

W. Seeger, R. Zamanian, M. Porres-Aguilar, 2010, Chest.

Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.

R. Barst, M. Fritzler, E. Angles-cano, 1997, American journal of respiratory and critical care medicine.

STARTS-2: Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Pediatric Pulmonary Arterial Hypertension

D. Ivy, G. Layton, M. Beghetti, 2014, Circulation.

Survival in Childhood Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management

R. Barst, M. Mcgoon, D. Ivy, 2011, Circulation.

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.

D. Ivy, L. Claussen, S. Abman, 2008, Journal of the American College of Cardiology.

Pulmonary arterial hypertension in children

R. Barst, A. Widlitz, R. Barst, 2003, European Respiratory Journal.

Direct quantitation of right and left ventricular volumes with nuclear magnetic resonance imaging in patients with primary pulmonary hypertension.

L. Boxt, R. Barst, J. Katz, 1992, Journal of the American College of Cardiology.

Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension.

W. Chung, Liyong Deng, R. Barst, 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Recent advances in the treatment of pediatric pulmonary artery hypertension.

R. Barst, R. Barst, 1999, Pediatric clinics of North America.

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

D. Badesch, D. Langleben, R. Bourge, 2000, Annals of internal medicine.

Familial pulmonary arterial hypertension, leucopenia, and atrial septal defect: a probable new familial syndrome with multisystem involvement

J. Knowles, R. Barst, A. Dursun, 2009, Clinical dysmorphology.

Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension.

R. Barst, R. Friedman, J. G. Mears, 1997, Circulation.

Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.

S. Hodge, J. Knowles, R. Barst, 2000, American journal of respiratory and critical care medicine.